What Happens If a Man Takes Abortion Pills?

A man who swallows the pills used in medication abortion will not experience anything resembling an abortion, but the drugs are not inert in a male body. The two-pill regimen consists of mifepristone and misoprostol, each with distinct pharmacological actions that go well beyond ending a pregnancy. In a man, these drugs interact with hormones, the digestive tract, and other systems in ways that range from mildly uncomfortable to medically measurable, though a single dose is unlikely to cause serious harm.

Two Different Drugs, Two Different Stories

Medication abortion uses two separate medications taken sequentially. Mifepristone, the first pill, is a progesterone and glucocorticoid receptor antagonist, meaning it blocks two types of hormone receptors in the body.¹ Misoprostol, the second pill (usually taken a day or two later), is a synthetic prostaglandin originally developed to protect the stomach lining from ulcer damage.² In women, the combination works because mifepristone destabilizes the uterine lining and misoprostol triggers uterine contractions. A man has neither a uterus nor the hormonal environment of pregnancy, so the intended mechanism simply has nothing to act on. But both drugs have effects elsewhere in the body that apply regardless of sex.

What Mifepristone Does in a Male Body

Most people think of mifepristone purely as an abortion drug, but its pharmacology is broader than that. It blocks progesterone receptors, which matter less in men than in women, and it also blocks glucocorticoid receptors, which matter a great deal. Glucocorticoid receptors are part of the system that regulates cortisol, the body’s primary stress hormone. Men and women share this system almost identically.

When mifepristone blocks glucocorticoid receptors, the brain’s feedback loop detects that cortisol is not getting through and responds by telling the adrenal glands to produce more. A study in healthy men found that mifepristone administration increased the morning surges of both ACTH (the hormone that tells the adrenals to work harder) and cortisol itself.³ The body is essentially trying to overcome the blockade by flooding the system with more of the hormone being blocked. From a single dose, this spike is temporary and resolves on its own. But it illustrates that the drug is not pharmacologically silent in men.

The glucocorticoid-blocking effect also has a downstream impact on androgens. In a phase II study of mifepristone in men with castration-resistant prostate cancer, researchers found that after one month of treatment, testosterone levels rose by about 91% and DHT (a potent form of testosterone) increased by roughly 80% compared to baseline.⁴ That study involved repeated dosing over weeks, not a single pill, so a one-time dose would not produce such dramatic hormonal shifts. Still, the mechanism is the same: blocking glucocorticoid receptors causes a cascade that nudges adrenal androgen production upward.

What Misoprostol Does in a Male Body

Misoprostol was actually developed and first approved for use in both men and women as a stomach-protective drug. It mimics natural prostaglandin E1, suppressing gastric acid secretion and strengthening the stomach’s mucous lining.² Its ability to cause uterine contractions was discovered later and repurposed for obstetric and gynecological use.⁵

In a man’s body, misoprostol does what it was originally designed to do: it acts on the gastrointestinal tract. The prostaglandin receptors it targets are present throughout the gut in both sexes. A single dose would reduce stomach acid production and speed up the movement of food through the intestines. For someone not expecting these effects, the result is usually gastrointestinal discomfort.

Side Effects a Man Would Actually Feel

The most noticeable effects from a single encounter with these pills would come from the misoprostol, not the mifepristone. Research on misoprostol’s gastrointestinal effects has found that the drug causes looser stools with higher water content, along with urgency, flatulence, abdominal pain, and nausea.⁶ These symptoms are dose-related, meaning they get worse at higher doses.⁷ The dose used in medication abortion (typically 800 micrograms) is considerably higher than the doses studied for stomach protection (100 to 200 micrograms), so a man taking the abortion-protocol dose would likely experience more pronounced GI symptoms than someone taking the drug for ulcer prevention.

Diarrhea and cramping are the headline symptoms. They tend to come on within a few hours and usually resolve within a day. Mifepristone’s effects are subtler from the outside. You might feel somewhat off, perhaps slightly fatigued or out of sorts, as the cortisol feedback loop gets temporarily disrupted, but there is unlikely to be anything dramatic. A study that examined cardiovascular effects of misoprostol in men found small, transient changes in blood flow and heart rate that were not considered clinically significant.⁸ In other words, a single dose is not going to land a healthy man in the emergency room.

At the lower doses used in stomach-protection trials, side effects were even milder. One study of misoprostol given alongside aspirin in men found no significant changes in laboratory values and no major side effects.⁹ The difference between that comfortable experience and the crampy, unpleasant one described above comes down almost entirely to dose.

Why Doctors Actually Prescribe These Drugs to Men

Both mifepristone and misoprostol have legitimate, FDA-recognized medical uses in men that have nothing to do with pregnancy. Understanding this context helps explain why their effects in the male body are well-documented.

Mifepristone was approved by the FDA in 2012 for managing Cushing’s syndrome, a condition caused by chronically elevated cortisol that affects men and women alike. In patients with Cushing’s who were not candidates for surgery or who had not achieved remission from surgery, about 60% responded to mifepristone with improvements in blood sugar control, and roughly 38% saw a reduction in diastolic blood pressure.¹⁰ The drug works in this context precisely because of its glucocorticoid-blocking properties; it prevents cortisol from acting on its receptors, which helps normalize blood sugar and blood pressure in people whose bodies are making too much cortisol.¹¹

Misoprostol has been prescribed to men for decades as a preventive measure against stomach ulcers caused by long-term use of nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen. A large placebo-controlled trial in patients with osteoarthritis found that gastric ulcers occurred in about 22% of the placebo group but in fewer than 6% of those taking misoprostol at 100 micrograms and only about 1.4% at 200 micrograms.¹² Subsequent research confirmed that misoprostol taken two or three times daily offered substantial protection against both gastric and duodenal ulcers in patients on long-term NSAID therapy.¹³ Many of those patients were men, and the drug’s safety profile in that context is well-established.

Effects on Sperm and Male Fertility

One question that comes up is whether either drug could affect a man’s fertility. The evidence is limited and mostly indirect, but there are some data points worth knowing about.

Mifepristone’s ability to increase testosterone and DHT levels, as seen in the prostate cancer study mentioned earlier, could theoretically affect spermatogenesis if sustained over time. A single dose is extremely unlikely to matter, but chronic use could disrupt the hormonal balance that governs sperm production. This is a theoretical concern rather than something documented in clinical studies of one-time exposure.

For misoprostol, the evidence is more direct but comes from laboratory rather than human studies. Research examining the effect of misoprostol on stallion semen found that when sperm were mixed with the drug in vitro, total motility dropped significantly at higher concentrations, with the strongest concentration reducing motility by about 18 percentage points compared to controls.¹⁴ This involved direct contact between the drug and sperm cells in a lab dish at concentrations far higher than what would reach the reproductive tract after swallowing a pill. Oral misoprostol is rapidly metabolized in the gut and liver before it ever reaches systemic circulation, so the practical relevance for a man who swallows a pill is unclear at best.

How Quickly the Drugs Leave Your System

Neither drug lingers for very long. Misoprostol itself is not even detectable in plasma after oral dosing; it gets rapidly converted by the body into its active metabolite, misoprostol acid, through a process called de-esterification. That metabolite then undergoes further breakdown and is cleared relatively quickly.¹⁵ Peak blood levels of the active metabolite occur within about 30 minutes, and the compound has a short half-life, meaning most of it is gone within a few hours.

Mifepristone sticks around longer. It has a much longer half-life, on the order of one to two days, and is metabolized through the liver into several breakdown products.¹⁶ The hormonal effects described earlier, including elevated cortisol and temporary androgen changes, would track roughly with this timeline, gradually fading as the drug is cleared. Within a few days, a healthy man’s hormone levels would return to baseline.

The Immune System Angle

Prostaglandins are not just gut hormones. They play roles in inflammation and immune regulation throughout the body. Misoprostol, because it mimics prostaglandin E1, can influence immune cell behavior. Research has shown that misoprostol binds the same receptors as natural prostaglandins E1, E2, and E3 and triggers intracellular signaling that modulates inflammatory cytokines and immune functions.¹⁷ In practical terms, prostaglandins of the E type tend to dial down certain inflammatory responses and shift immune activity in subtle ways.

For a man taking a single dose, this immune modulation is transient and mild. The body already produces prostaglandins constantly; adding a synthetic one temporarily raises the signal but does not overwhelm the system. Researchers studying misoprostol for other purposes have not flagged immune suppression as a meaningful risk from short-term use. This angle is more relevant for people considering chronic use, such as long-term NSAID users taking misoprostol daily for stomach protection, where the cumulative immunomodulatory effects deserve at least some clinical attention.

Why the Question Keeps Coming Up

This question circulates partly because of viral social media posts and partly because of genuine curiosity about pharmacology. Some people imagine the pills would cause dramatic, visible symptoms in a man, perhaps expecting something analogous to what a woman experiences during a medication abortion (heavy bleeding, strong cramping). That does not happen, because the organs responsible for those symptoms are not present. The uterine contractions and endometrial shedding that make medication abortion uncomfortable for women have no male equivalent.

Others ask out of concern for safety, wondering whether accidental ingestion could be dangerous. For a healthy adult man, a single dose of either drug is not considered dangerous, though the GI side effects from misoprostol can be unpleasant. The situation would be different for someone with specific medical conditions. A man with adrenal insufficiency, for instance, should not be casually exposed to a glucocorticoid antagonist like mifepristone, because his body already struggles to produce or respond to cortisol. Similarly, someone with active gastrointestinal bleeding or severe inflammatory bowel disease could have their condition worsened by a large dose of misoprostol. But for the average healthy man, the experience would amount to an unpleasant stomach day and some hormonal blips that resolve on their own.

The Prostate Cancer Chapter

Mifepristone has had a quiet but interesting history in prostate cancer research. The rationale for studying it was that some prostate cancer cells express progesterone receptors, and blocking those receptors might slow tumor growth. The phase II trial mentioned earlier tested this idea in men with castration-resistant prostate cancer, the form of the disease that continues to progress even after testosterone suppression therapy. The results were disappointing from an oncology standpoint: the drug did not show meaningful anti-tumor activity. What the study did reveal, though, was that mifepristone significantly increased circulating androgen levels in these men, with testosterone nearly doubling after a month of treatment.⁴ That finding essentially closed the door on mifepristone as a prostate cancer therapy, since raising testosterone in a testosterone-sensitive cancer is counterproductive. But it added valuable data on what the drug does to male hormone levels, data that helps answer the broader question of what happens when a man takes it.

The Cushing’s syndrome application remains viable precisely because the cortisol-blocking effect is the therapeutic goal there, and the androgen-boosting side effect is manageable under medical supervision. It is a reminder that the same pharmacological action can be therapeutic in one disease and harmful in another, depending entirely on the patient’s hormonal context.